ALK and non-small cell lung carcinoma: However, patients with driver gene-positive NSCLC represented by EGFR and ALK have been considered unable to benefit from immunotherapy 12, and most clinical trials on immune checkpoint inhibitors have excluded such patients, and we do not know the efficacy of immunotherapy for patients with driver gene mutations.